SCHEMBL6802249

SCHEMBL6802249

CN(CCCOc1ccc(C=O)cc1)c1nc2ccccc2o1

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 10/20 0.57
ATP4A P20648 9/20 0.56
ATP4B P51164 9/20 0.56
PPARA Q07869 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6806357 0.97 ATP4A (0.57) PPARGATP4AATP4BPPARA
SCHEMBL4744468 0.94 PPARG (0.63) PPARGATP4AATP4BPPARA
SCHEMBL8721223 0.86 PPARG (0.58) PPARGATP4AATP4BPPARA
SCHEMBL8721219 0.85 PPARG (0.57) PPARGATP4AATP4BPPARA
SCHEMBL8721221 0.85 PPARG (0.57) PPARGATP4AATP4BPPARA
SCHEMBL5275039 0.83 PPARG (0.64) PPARGPPARA
SCHEMBL1848111 0.83 PPARG (0.61) PPARG
SCHEMBL1848112 0.83 PPARG (0.61) PPARG
SCHEMBL12521873 0.83 PPARG (0.61) PPARG
SCHEMBL8716289 0.83 PPARG (0.48) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686475-B2 THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES BEECHAM GROUP P.L.C. (GB) 2004-02-03 US disclosed
US-20030149054-A1 Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal BEECHAM GROUP P.L.C. 2003-08-07 US disclosed
US-20020049240-A1 NOVEL COMPOUNDS BEECHAM GROUP P.1.C. 2002-04-25 US disclosed
US-6288095-B1 ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC BEECHAM GROUP P.L.C. (GB) 2001-09-11 US disclosed
EP-0306228-B1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1999-11-17 EP disclosed
EP-0842925-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1998-05-20 EP disclosed
US-5646169-A ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS BEECHAM GROUP P.L.C. (GB) 1997-07-08 US disclosed
US-5521201-A SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES BEECHAM GROUP P.L.C. 1996-05-28 US disclosed
US-5260445-A Hypoglycemic BEECHAM GROUP P.L.C. (GB) 1993-11-09 US disclosed
US-5232925-A Treating hypertension BEECHAM GROUP P.L.C. (GB) 1993-08-03 US disclosed
US-5194443-A Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents BEECHAM GROUP P.L.C. (GB) 1993-03-16 US disclosed
US-5002953-A Substituted Thiazolidinedione Derivatives BEECHAM GROUP P.L.C. (GB) 1991-03-26 US disclosed
EP-0306228-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1989-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149054-A1 Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal TYK2, FABP3, FABP4 PPARG 16/4885ATP4A 1793/4885ATP4B 3152/4885
US-20020049240-A1 NOVEL COMPOUNDS GRK1, GRK3, GRK7 PPARG 715/4885ATP4A 2743/4885ATP4B 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.